New NICE Approval: Dabrafenib-Trametinib

posted in: NICE News | 0

BTOG wishes to inform members of a new NICE approval that has been published today.

NICE has now reappraised dabrafenib-trametinib for BRAF V600E mutant advanced NSCLC and given a positive recommendation for the submitted indication: 1st line BRAF V600E advanced NSCLC.

For further details and the documents, please see the NICE website.

We are informed that 1st line patients currently receiving dabrafenib-trametinib under COVID interim access will need to be re-registered on BluTeq (the software used to register patients and sets the criteria for eligibility that prescribers use to request NHSE approval for each case), and that the COVID interim access for 2nd line patients will be taken down on 18th May.